| Drospirenone and its antialdosterone properties. | |
| | |
MedLine Citation:
|
PMID: 17364593 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Drospirenone is a unique progestogen derived from 17alpha-spirolactone, with a pharmacologic profile very similar to that of endogenous progesterone. In contrast with other available progestins, drospirenone is a progestogen with aldosterone receptor antagonism (PARA) through its affinity for the mineralocorticoid receptor. It is thus able to act on the renin-angiotensin-aldosterone system (RAAS), which prevents excessive sodium loss and regulates blood pressure. Estrogen acts on the RAAS to stimulate the synthesis of angiotensinogen, which increases aldosterone levels and promotes sodium and water retention. When these effects are unopposed, for example during estrogen replacement therapy, they can lead to increases in weight and blood pressure. The antialdosterone properties exhibited by drospirenone promote sodium excretion and prevent water retention, conferring potential blood pressure benefits. In addition to its effects on the kidney, aldosterone has effects on the vasculature, myocardium and central nervous system, which may elicit a variety of pathophysiologic processes associated with cardiovascular disease. The antialdosterone properties of drospirenone may therefore confer additional cardiovascular benefits beyond the RAAS system. The combined actions of drospirenone on sodium and water retention and cardiovascular parameters make it a more attractive therapeutic option as a component of hormone replacement therapy than other synthetic progestins. |
| | |
Authors:
|
A R Genazzani; P Mannella; T Simoncini |
Related Documents
:
|
11408393 - Et(a) receptor antagonist prevents blood pressure elevation and vascular remodeling in ... 20720523 - Bk channels and a new form of hypertension. 1326903 - Chronic alcohol intake induces reversible disturbances on cellular na+ metabolism in hu... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Climacteric : the journal of the International Menopause Society Volume: 10 Suppl 1 ISSN: 1369-7137 ISO Abbreviation: Climacteric Publication Date: 2007 Feb |
Date Detail:
|
Created Date: 2007-03-16 Completed Date: 2007-05-01 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9810959 Medline TA: Climacteric Country: United States |
Other Details:
|
Languages: eng Pagination: 11-8 Citation Subset: IM |
Affiliation:
|
Department of Obstetrics and Gynecology, University of Pisa, Pisa, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aldosterone Antagonists
/
pharmacology* Androstenes / pharmacology* Cardiovascular System / drug effects Female Humans Nitric Oxide Synthase Type III / drug effects, metabolism Renin-Angiotensin System / drug effects* |
| Chemical | |
Reg. No./Substance:
|
0/Aldosterone Antagonists; 0/Androstenes; 67392-87-4/drospirenone; EC 1.14.13.39/Nitric Oxide Synthase Type III |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Drospirenone and estradiol: a new option for the postmenopausal woman.
Next Document: Menopause and cardiovascular disease: the evidence.